Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
PR Newswire
VALBY, Denmark, June 15, 2026
Asedebart is an investigational monoclonal antibody designed to neutralize excess adrenocorticotropic hormone (ACTH) and reduce downstream cortisol production in Cushing's disease (CD)Urinary free cortisol (UFC) normalization is a clinically relevant measure in CD, where chronic cortisol excess is a key driver of morbidity, mortality and quality-of-life burdenPreliminary Phase II Part A data showed UFC normalization in most evaluable adults with CD who completed individualized intravenous dose titration with asedebart1VALBY, Denmark, June 15, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced preliminary Phase II Part A data from its ongoing study evaluating asedebart (Lu AG13909), an anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, in adults with Cushing's disease (CD). CD is characterized by overproduction of ACTH by a pituitary adenoma and involves dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis.2 Urinary free cortisol (UFC) is a key measure of cortisol burden in CD, where chronic hypercortisolism is central to CD's clinical impact. Asedebart's mechanism of action aims to neutralize pathological increases in ACTH and thereby affect downstream chronic cortisol excess, as reflected in UFC levels.
